
Dr. Pranjal Bordoloi
Dr. Pranjal P. Bordoloi brings over two decades of diverse experience in clinical research, pharmacovigilance, regulatory affairs, and strategic operations across the pharmaceutical, biotechnology, and CRO sectors. His career is marked by a strong integration of scientific acumen and operational leadership, with a consistent track record of driving global clinical development programs and delivering high-impact outcomes.
Throughout his career, Dr. Bordoloi has successfully led more than 100 clinical trials spanning Phases I to IV, including NCEs, ANDA, and Biosimilar studies. His therapeutic expertise spans a wide range of indications, including rare and orphan diseases, and he has extensive experience navigating regulatory frameworks across India, the US, EU, and other international markets.
Dr. Bordoloi holds an MBBS from Assam Medical College (Dibrugarh University), an MD in Pharmacology from Gauhati Medical College (Gauhati University), a PGDBM from the Assam Institute of Management, and has completed an Advanced Program in Strategy Management from the Indian Institute of Management, Kolkata.
At Lambda, Dr. Bordoloi leads cross-functional teams encompassing clinical operations, medical affairs, regulatory, pharmacovigilance, and data management and biostatistics. A recognized thought leader, Dr. Bordoloi is a frequent speaker at national and international conferences, where he shares insights on clinical trial management, biosimilars, and pharmacovigilance. His strategic vision and commitment to quality continue to drive innovation and growth within the organization.

"At Lambda–Novum, I believe meaningful research begins with empowered teams and clear, collaborative processes. By combining scientific rigor with thoughtful planning, we deliver clinical trials that not only meet global standards but also make a real difference in patients’ lives."
Dr. Pranjal P. Bordoloi brings over two decades of diverse experience in clinical research, pharmacovigilance, regulatory affairs, and strategic operations across the pharmaceutical, biotechnology, and CRO sectors. His career is marked by a strong integration of scientific acumen and operational leadership, with a consistent track record of driving global clinical development programs and delivering high-impact outcomes.
Throughout his career, Dr. Bordoloi has successfully led more than 100 clinical trials spanning Phases I to IV, including NCEs, ANDA, and Biosimilar studies. His therapeutic expertise spans a wide range of indications, including rare and orphan diseases, and he has extensive experience navigating regulatory frameworks across India, the US, EU, and other international markets.
Dr. Bordoloi holds an MBBS from Assam Medical College (Dibrugarh University), an MD in Pharmacology from Gauhati Medical College (Gauhati University), a PGDBM from the Assam Institute of Management, and has completed an Advanced Program in Strategy Management from the Indian Institute of Management, Kolkata.
At Lambda, Dr. Bordoloi leads cross-functional teams encompassing clinical operations, medical affairs, regulatory, pharmacovigilance, and data management and biostatistics. A recognized thought leader, Dr. Bordoloi is a frequent speaker at national and international conferences, where he shares insights on clinical trial management, biosimilars, and pharmacovigilance. His strategic vision and commitment to quality continue to drive innovation and growth within the organization.

"At Lambda–Novum, I believe meaningful research begins with empowered teams and clear, collaborative processes. By combining scientific rigor with thoughtful planning, we deliver clinical trials that not only meet global standards but also make a real difference in patients’ lives."






